Landmark trials in endocrine adjuvant therapy for breast carcinoma

被引：12

作者：

Gradishar, W ^{[1
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

来源：

CANCER | 2006年 / 106卷 / 05期

关键词：

breast carcinoma; endocrine adjuvant therapy; tamoxifen; aromatase inhibitors; clinical trials;

D O I：

10.1002/cncr.21707

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The review summarizes the outcomes of several landmark trials involving aromatase inhibitors that helped formulate current therapeutic approaches recommended by the American Society of Clinical Oncology for breast carcinoma treatment.

引用

页码：975 / 981

页数：7

共 29 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2]

Abram P, 1996, J NATL CANCER I, V88, P1834

[3]

[Anonymous], 1983, Lancet, V1, P257

[4]

*ASTRAZENECA PHAR, 2004, AR PACK INS

[5]

Baum M, 2002, LANCET, V359, P2131

[6] Aromatase inhibitors in advanced breast cancer: there are efficacy differences [J].

Bhatnagar, AS .

BRITISH JOURNAL OF CANCER, 2005, 92 (06) :1173-1174

[7]

BHATNAGAR AS, 1996, HORMONE DEPENDENT CA, P155

[8] Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer - Reply [J].

Buzdar, AU ;

Theriault, RL ;

Hunt, KK ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7760-7761

[9]

Clarke M, 1998, LANCET, V351, P1451

[10]

*CLIN TRIAL SERV U, 1995, ADJ TAM LONG SHORT A

← 1 2 3 →